Abstract
Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.
| Original language | English |
|---|---|
| Pages (from-to) | 188le2 |
| Journal | Science Translational Medicine |
| Volume | 5 |
| Issue number | 188 |
| DOIs | |
| Publication status | Published - 5 Jun 2013 |
Keywords
- Amyotrophic Lateral Sclerosis/pathology
- Drug Evaluation, Preclinical/methods
- Humans
- Induced Pluripotent Stem Cells/cytology
- Motor Neurons/cytology
Fingerprint
Dive into the research topics of 'Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells"'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver